<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Arbutus Biopharma Corporation

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Arbutus Biopharma Corporation

    Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      William H. Collier
    • FOUNDED
      1992
    • EMPLOYEES
      51-100
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Aimmune Therapeutics, Inc.

    Aimmune Therapeutics, Inc.

    Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a clinical-stage biopharmaceutical c...

    Aimmune Therapeutics, Inc. (Nasdaq: AIMT), is a...

    Filing Type:    PU
    Alnylam Pharmaceuticals, Inc.

    Alnylam Pharmaceuticals, Inc.

    Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...

    Alnylam is leading the translation of RNA inter...

    Filing Type:    PU
    Celldex Therapeutics, Inc.

    Celldex Therapeutics, Inc.

    Celldex is developing targeted therapeutics to address devastating diseases for wh...

    Celldex is developing targeted therapeutics to ...

    Filing Type:    PU
    Lifevantage Corporation

    Lifevantage Corporation

    LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...

    LifeVantage Corporation (Nasdaq: LFVN) is a pio...

    Filing Type:    PU
    Axovant Gene Therapies Ltd.

    Axovant Gene Therapies Ltd.

    Axovant is accelerating the development of innovative gene therapy products that a...

    Axovant is accelerating the development of inno...

    Filing Type:    PU
    CytomX Therapeutics, Inc.

    CytomX Therapeutics, Inc.

    CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. ...

    CytomX Therapeutics develops Probody™ therape...

    Filing Type:    PU
    Spring Bank Pharmaceuticals, Inc.

    Spring Bank Pharmaceuticals, Inc.

    Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...

    Spring Bank is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    Assembly Biosciences, Inc.

    Assembly Biosciences, Inc.

    Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...

    Assembly Biosciences is advancing a new class o...

    Filing Type:    PU
    VBI Vaccines, Inc.

    VBI Vaccines, Inc.

    VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...

    VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.